Inotiv, Inc.

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inotiv, Inc. reports robust Q4 earnings, eyes sales growth opportunities

Inotiv, Inc. delivered strong financial performance in Q4 2022, with a focus on revenue growth and margin enhancement. Despite challenges in the NHP business and operational disruptions, the company remains optimistic about future prospects and anticipates significant sales growth from recent price increases.

Inotiv reports robust revenue growth in Q1 2023 earnings call

Inotiv Inc. demonstrated strong revenue growth in Q1 2023, despite facing challenges with negative adjusted EBITDA. The company's focus on cost reductions, pricing increases, and operational enhancements presents opportunities for future growth. Inotiv remains optimistic about its future prospects, having made tough decisions to improve its performance.

Inotiv reports revenue growth and EBITDA improvement, faces guidance challenges

Inotiv's Q2 showed revenue growth and EBITDA improvement, driven by DSA and RMS segments. Despite challenges with increased expenses and guidance adjustments, the company remains focused on margin improvements, supplier vetting, and investor engagement.

Inotiv reports robust Q3 earnings amidst NHP supply challenges

Inotiv's Q3 2023 earnings call highlighted strong financial performance, strategic initiatives, and challenges related to NHP supply.
The company's focus on operational optimization, cost reduction, and growth opportunities underscores a commitment to sustainable expansion.
Despite industry challenges, Inotiv remains confident in achieving long-term EBITDA margins of 18-22% and is actively addressing supply chain issues.
Proactive measures to manage NHP supply challenges and explore revenue growth opportunities position Inotiv for continued success in the CRO industry.

Inotiv reports robust fiscal 2023 performance and strategic growth outlook

Inotiv's strong fiscal performance in 2023 and strategic initiatives position the company for continued growth and operational excellence in 2024.
While challenges in the NHP market and uncertainties in certain service segments exist, Inotiv's focus on innovation and efficiency mitigates potential risks.
Opportunities for revenue growth through service expansion, cost reductions, and customer relationship enhancement underscore a positive outlook for the company.
By leveraging strengths in operational efficiency, service quality, and market positioning, Inotiv aims to solidify its position as a leading CRO provider and drive sustainable growth.

Inotiv reports strong Q1 results, eyes growth through acquisitions

Inotiv's Q1 performance reflects positive momentum with revenue growth and improved profitability. The company's strategic focus on operational efficiency, acquisitions, and expansion sets the stage for future success. Challenges lie in sustaining growth through effective cost management and operational optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

NEW YORK , Aug. 15, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inotiv, Inc. ("Inotiv" or "the Company") (NASDAQ: NOTV). Investors who purchased Inotiv securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/notv.

Inotiv, Inc. (NOTV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Inotiv, Inc. (NASDAQ:NOTV ) Q3 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bob Yedid - LifeSci Advisors, Investor Relations Bob Leasure - Chief Executive Officer, President, and Director Beth Taylor - Senior Vice President of Finance and Chief Financial Officer Conference Call Participants Tim Daley - Wells Fargo Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Frank Takkinen - Lake Street Capital Markets Yuan Zhi - B. Riley Operator Good afternoon, ladies and gentlemen.

Inotiv, Inc. (NOTV) Q3 2023 Earnings Call Transcript

Inotiv, Inc. (NOTV) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.26 per share. This compares to loss of $0.15 per share a year ago.

Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates

WEST LAFAYETTE, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q3 FY 2023”) and nine months (“YTD FY 2023”) ended June 30, 2023.

Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update

WEST LAFAYETTE, Ind., July 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023

Inotiv, Inc. (NOTV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength?

The consensus price target hints at an 185.1% upside potential for Inotiv, Inc. (NOTV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Inotiv, Inc. (NOTV) Have the Potential to Rally 185.14% as Wall Street Analysts Expect?

Compania Cervecerias Unidas

JinkoSolar Holding

Wabash National

In the realm of value investing, the earnings yield metric serves as a powerful tool for identifying undervalued stocks with solid long-term growth potential. CCU, WNC, LOMA, JKS and NOTV are worth buying.

5 High Earnings Yield Gems for Successful Value Investing

Inotiv, Inc. (NOTV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV)

WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023. Management will also be available for one-on-one meetings.

Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference

WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences:

Inotiv, Inc. to Participate in May Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 169% in Inotiv, Inc. (NOTV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know

Inotiv, Inc. (NASDAQ:NOTV ) Q2 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Devin Sullivan – Investor Relations-The Equity Group Bob Leasure – President and Chief Executive Officer Beth Taylor – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Dave Windley – Jefferies Frank Takkinen – Lake Street Capital Markets Operator Good afternoon, and welcome to Inotiv's Second Quarter Fiscal 2023 Financial Results Conference Call. At this time all participants are in listen-only mode.

Inotiv, Inc. (NOTV) Q2 2023 Earnings Call Transcript

Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.24 per share a year ago.

Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

WEST LAFAYETTE, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company's safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv's Discovery and Safety Assessment business, telemetry allows for the continuous observation of ECG, respiratory rate and volume, blood pressure and other cardiovascular parameters during preclinical safety studies.

Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry

WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023

Inotiv, Inc. (NASDAQ:NOTV ) Q1 2023 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Devin Sullivan - The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets David Windley - Jefferies Tim Daley - Wells Fargo Operator Hello, and welcome to Inotiv Inc.'s First Quarter Fiscal 2023 Financial Results Conference Call and Webcast. A question-and-answer session will follow the formal presentation.

Inotiv, Inc. (NOTV) Q1 2023 Earnings Call Transcript

Reiterates Select Full Year Fiscal 2023 Financial Guidance Reiterates Select Full Year Fiscal 2023 Financial Guidance

Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results

WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023

WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 15-year history of surveying more than 20 million employees and recognizing the top organizations across 60 markets for regional Top Workplaces awards.

Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award

WEST LAFAYETTE, Ind., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to focus on his position as Partner at AS Birch Grove.

Inotiv, Inc. Announces Changes to Board of Directors

The stock may have found its bottom in December 2022. Revenue jumped 400 percent in the fourth fiscal quarter, but earnings plummeted.

Inotiv: Turning Focus To Organic Growth

Inotiv's recently acquired companies cause its revenue to spike tremendously. However, the company's expenses are just as great, and not all of the largest cost items are one-time costs, meaning the company could remain unprofitable for a long time.

Inotiv: High Expenses Likely To Impair Long-Term Profitability

Inotiv, Inc. (NASDAQ:NOTV ) Q4 2022 Earnings Conference Call January 10, 2023 5:00 PM ET Company Participants Devin Sullivan - Investor Relations, The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Greetings, and welcome to the Inotiv, Inc.'s Fourth Quarter and Full Year Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Inotiv, Inc. (NOTV) Q4 2022 Results - Earnings Call Transcript

Provides Select First Quarter and Full Year Fiscal 2023 Financial Guidance Provides Select First Quarter and Full Year Fiscal 2023 Financial Guidance

News for Inotiv, Inc. Stock (NOTV)